EGA: EU generics makers could fall behind; Zydus to buy KV's Nesher unit;

@FiercePharma: U.K. officials fault Pfizer in Sandwich closure. Item | Follow @FiercePharma 

> Europe's generic drugmakers could fall behind the likes of India and South Korea if they do not receive more support from the continent's legislators. This was one of the key points to come out of the annual conference of European Generic medicines Association (EGA) held in Lisbon. Article

> Zydus Pharmaceuticals USA has entered into an agreement to acquire the assets of the U.S.-based Nesher Pharmaceuticals, which operates as the generic subsidiary of KV Pharmaceutical. The financial details of the agreement are undisclosed. Zydus release

> The U.S. District Court for the Southern District of New York has dismissed a motion for summary judgment on Copaxone filed by Teva Pharmaceutical Industries. Teva filed the motion for a summary judgment finding of no inequitable conduct as part of its lawsuit to block efforts by Mylan to develop a generic version of Copaxone for the treatment of multiple sclerosis. Story

> A trans-Tasman medicines watchdog could become a reality within five years after Prime Minister Julia Gillard signed a statement of intent with her New Zealand counterpart John Key. Report

> The U.S. Supreme Court heads into the last two weeks of its term Monday, facing a final round of decisions on matters as varied as violent video games, global warming, drug prescription records and alleged gender bias at Wal-Mart stores. The court will decide whether generic drug makers can be sued for failing to warn patients about newly revealed dangers. News

Biotech News

@FierceBiotech: Regeneron eye drug gets green flag at AdComm. Item | Follow @FierceBiotech

@JohnCFierce: It's off to Paris tonight and some sitdowns with the Europeans next week. Still working, though, so keep the tweets and emails coming. Follow @JohnCFierce

> Roche preps vismodegib app after Ph2 skin cancer success. Item

> Acura shares spike on FDA painkiller approval, $20M Pfizer milestone. Report 

> Case against 3M opens in the U.K. News

Biotech IT News

> PerkinElmer, others ride 'wave' of genomic data going to the cloud. News

> Knome automates analysis of NGS data, evolves in genomics field. Report 

> Supercomputing poised for leading R&D role in personalized medicine. Story

> AstraZeneca plans tech center in Russia, aims to use informatics to predict drug safety. Item

> Brown U. program crunches data on mutations behind disease. News

> Public funds costly for Aussie life sciences supercomputing plan? Piece

Medical Device News

> Medtronic reports positive results with Valiant. Item

> Philips, ROSATOM ink nuclear medicine MOU. Report 

> Case against 3M opens in the U.K. Story

> Jan Medical nabs $3.15M in Series A. News

> Life Core names new CEO. Story 

And Finally... India's huge population makes it one of the world's most promising markets for drug research. But as the $400 million business accelerates, critics say it is exposing the dark side of the country's healthcare sector. Story

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.